Future Research

Among the different experimental strategies in the treatment of Hodgkin's lymphoma, antibody-based constructs have given the most promising results in experimental Hodgkin's lymphoma models. Early clinical trials using immunotoxins and, more recently, monoclonal antibodies (MoAb) have demonstrated some clinical efficacy in patients with refractory Hodgkin's lymphoma.

Hodgkin's lymphoma can be a suitable candidate for MoAb-based therapy because Reed-Sternberg and Hodgkin's cells express specific surface antigens such as CD15, CD25, and CD30. So far, different approaches to eradicate tumor cells have been utilized using antibodies, including "naked" MoAb, and bispecific constructs that activate effectors cells of immune system against the target cell, immunotoxins that deliver a toxin linked to a specific antibody into the target cell, and different radioimmunoconjugates.

0 0

Post a comment